| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,370,000 |
| Market
Cap: |
51.66(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.95 - $28.58 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BioXcel Therapeutics is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. Co.'s two key clinical development programs are BXCL501, an investigational, proprietary, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naive to checkpoint inhibitors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
9,589 |
9,589 |
82,874 |
411,951 |
| Total Sell Value |
$25,207 |
$25,207 |
$1,629,204 |
$8,459,925 |
| Total People Sold |
6 |
6 |
6 |
7 |
| Total Sell Transactions |
6 |
6 |
11 |
24 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oneill Vincent |
See Remarks |
• – – |
2024-04-04 |
4 |
AS |
$2.62 |
$432 |
D/D |
(165) |
5,408 |
|
-4% |
|
| Rodriguez Javier |
See Remarks |
• – – |
2024-04-04 |
4 |
AS |
$2.64 |
$2,667 |
D/D |
(1,012) |
7,672 |
|
-4% |
|
| Wiley Matthew T. |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-04-04 |
4 |
AS |
$2.64 |
$2,656 |
D/D |
(1,008) |
2,992 |
|
-4% |
|
| Mehta Vimal |
CEO and President |
• • – |
2024-04-04 |
4 |
AS |
$2.62 |
$13,823 |
D/D |
(5,268) |
43,564 |
|
-4% |
|
| Yocca Frank |
Chief Scientific Officer |
• – – |
2024-04-04 |
4 |
AS |
$2.64 |
$2,812 |
D/D |
(1,067) |
12,763 |
|
-4% |
|
| Steinhart Richard I |
Chief Financial Officer |
• – – |
2024-04-04 |
4 |
AS |
$2.64 |
$2,817 |
D/D |
(1,069) |
4,765 |
|
-4% |
|
| Oneill Vincent |
See Remarks |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
5,573 |
|
- |
|
| Rodriguez Javier |
See Remarks |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
8,684 |
|
- |
|
| Wiley Matthew T. |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Mehta Vimal |
CEO and President |
• • – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,000 |
48,832 |
|
- |
|
| Yocca Frank |
Chief Scientific Officer |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
13,830 |
|
- |
|
| Steinhart Richard I |
Chief Financial Officer |
• – – |
2024-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
5,834 |
|
- |
|
| Oneill Vincent |
See Remarks |
• – – |
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
3,323 |
|
- |
|
| Rodriguez Javier |
See Remarks |
• – – |
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
6,434 |
|
- |
|
| Mehta Vimal |
CEO and President |
• • – |
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,610 |
34,832 |
|
- |
|
| Yocca Frank |
Chief Scientific Officer |
• – – |
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
11,580 |
|
- |
|
| Steinhart Richard I |
Chief Financial Officer |
• – – |
2024-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
3,584 |
|
- |
|
| Oneill Vincent |
Chief Medical Officer |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
2,802 |
|
- |
|
| Yocca Frank |
Chief Scientific Officer |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
11,059 |
|
- |
|
| Rodriguez Javier |
See Remarks |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
5,913 |
|
- |
|
| Steinhart Richard I |
Chief Financial Officer |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
3,063 |
|
- |
|
| Mehta Vimal |
CEO and President |
• • – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,609 |
32,222 |
|
- |
|
| Oneill Vincent |
Chief Medical Officer |
• – – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
2,281 |
|
- |
|
| Steinhart Richard I |
Chief Financial Officer |
• – – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
521 |
2,542 |
|
- |
|
| Mehta Vimal |
CEO and President |
• • – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,610 |
29,613 |
|
- |
|
147 Records found
|
|
Page 1 of 6 |
|
|
0.23 (9.79%) 
